TSMRF Stock Chart & Stats
$23.29
$0.00(0.00%)
At close: 4:00 PM EDT
$23.29
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$20.27 - $25.95
Previous CloseN/A
Volume5.00
Average Volume (3M)0.00
Market Cap
$1.82B
Enterprise Value$400.01K
Total Cash (Recent Filing)$77.28B
Total Debt (Recent Filing)$148.07B
Price to Earnings (P/E)9.2
Beta-0.02
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.32%
Share Statistics
EPS (TTM)405.06
Shares Outstanding76,758,360
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)0.87
Price to Sales (P/S)1.45
P/FCF Ratio-34.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.19
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ExpansionThe multi-year revenue increase indicates sustained demand for Tsumura’s kampo portfolio and expanding commercial scale. Continued adoption through Japan’s healthcare system can support the company’s core prescription-led model over the medium term.
Strong ProfitabilityHealthy gross and net margins demonstrate that Tsumura’s specialized kampo products generate meaningful earnings after production and operating costs. This profitability provides resilience and supports reinvestment in manufacturing, products, and distribution.
Moderate Current LeverageDespite the recent increase in borrowings, leverage remains moderate relative to the company’s equity and asset base. This gives Tsumura a reasonable solvency foundation and some capacity to manage investment needs if cash generation improves.
Bears Say
Negative Free Cash FlowWeak cash conversion and negative free cash flow reduce the funds available for debt reduction, dividends, and strategic investment. If sustained, this gap could limit financial flexibility even though reported profitability remains strong.
Rising Debt BurdenThe substantial increase in debt raises reliance on a recovery in operating cash generation and increases financial risk if earnings or working-capital conditions weaken. It also reduces flexibility for future expansion and shareholder distributions.
Recent Growth And Margin SlowdownThe latest near-flat revenue performance suggests that the earlier expansion trend may be moderating. Margin normalization could further constrain earnings growth, making future performance more dependent on renewed product demand and operating efficiency.
Tsumura & Co News
TSMRF FAQ
What was Tsumura & Co.’s price range in the past 12 months?
Tsumura & Co. lowest stock price was $20.27 and its highest was $25.95 in the past 12 months.
What is Tsumura & Co.’s market cap?
Tsumura & Co.’s market cap is $1.82B.
When is Tsumura & Co.’s upcoming earnings report date?
Tsumura & Co.’s upcoming earnings report date is Nov 09, 2026 which is in 63 days.
How were Tsumura & Co.’s earnings last quarter?
Tsumura & Co. released its earnings results on Aug 06, 2026. The company reported $0.543 earnings per share for the quarter.
Is Tsumura & Co. overvalued?
According to Wall Street analysts Tsumura & Co.’s price is currently Overvalued.
Does Tsumura & Co. pay dividends?
Tsumura & Co. pays a Semiannually dividend of $0.507 which represents an annual dividend yield of 4.32%. See more information on Tsumura & Co. dividends here
What is Tsumura & Co.’s EPS estimate?
Tsumura & Co.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsumura & Co. have?
Tsumura & Co. has 76,758,360 shares outstanding.
What happened to Tsumura & Co.’s price movement after its last earnings report?
Tsumura & Co. reported an EPS of $0.543 in its last earnings report. Following the earnings report the stock price went up 0.345%.
Which hedge fund is a major shareholder of Tsumura & Co.?
Currently, no hedge funds are holding shares in TSMRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsumura & Co.
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extract intermediates and granular Kampo preparations. Its operations are comprehensive, encompassing the full supply chain: from the careful acquisition, selection, processing, and warehousing of raw herbal materials and crude drug components for decoctions, to the manufacturing of powdered Kampo extracts and traditional Chinese medicines. Additionally, Tsumura & Co. is engaged in the sale of both pharmaceutical goods and food products.
Technical Analysis
―
Kaken Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Pharma Foods International Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Ownership Overview
―
Insiders
6.82% Mutual Funds
― Other Institutional Investors
86.73% Public Companies and
Individual Investors